We might have to wait until the quarterly reports to know for...

We might have to wait until the quarterly reports to know for sure, even the FY18 annual report for that matter because big contracts like this tend to generate more cash flows towards the middle/end of the term.

If you think about it the fact that a $50m market cap company on ASX managed to convince a $10bn market cap company on NASDAQ to use their name in a public announcement is a strong indication that Abiomed considered Sensera to be an important partner in their supply chain. Generally the top dogs won't allow the puppies to use their brands for marketing purpose if they don't think there's something in it for them.